Literature DB >> 16759111

Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.

Rao V Kalla1, Elfatih Elzein, Thao Perry, Xiaofen Li, Venkata Palle, Vaibhav Varkhedkar, Arthur Gimbel, Tennig Maa, Dewan Zeng, Jeff Zablocki.   

Abstract

Adenosine has been suggested to induce bronchial hyperresponsiveness in asthmatics, which is believed to be an A(2B) adenosine receptor (AdoR) mediated pathway. We hypothesize that a selective, high-affinity A(2B) AdoR antagonist may provide therapeutic benefit in the treatment of asthma. In an attempt to identify a high-affinity, selective antagonist for the A(2B) AdoR, we synthesized 8-(C-4-pyrazolyl) xanthines. Compound 22, 8-(1H-pyrazol-4-yl)-1,3-dipropyl xanthine, is a N-1 unsubstituted pyrazole derivative that has favorable binding affinity (K(i) = 9 nM) for the A(2B) AdoR, but it is only 2-fold selective versus the A(1) AdoR. Introduction of a benzyl group at the N-1-pyrazole position of 22 resulted in 19, which had moderate selectivity. The initial focus of the SAR study was on the preparation of substituted benzyl derivatives of 19 because the corresponding phenyl, phenethyl, and phenpropyl derivatives showed a decrease in A(2B) AdoR affinity and selectivity relative to 19. The preferred substitution on the phenyl ring of 19 contains an electron-withdrawing group, specifically F or CF(3) at the m-position, as in 33 and 36 respectively, increases the selectivity while retaining the affinity for the A(2B) AdoR. Exploring disubstitutions on the phenyl ring of derivatives 33 and36 led to the 2-chloro-5-trifluoromethylphenyl derivative 50, which retained the A(2B) AdoR affinity but enhanced the selectivity relative to 36. After optimization of the substitution on the 8-pyrazole xanthine, 1,3-disubstitution of the xanthine core was explored with methyl, ethyl, butyl, and isobutyl groups. In comparison to the corresponding dipropyl analogues, the smaller 1,3-dialkyl groups (methyl and ethyl) increased the A(2B) AdoR binding selectivity of the xanthine derivatives while retaining the affinity. However, the larger 1,3-dialkyl groups (isobutyl and butyl) resulted in a decrease in both A(2B) AdoR affinity and selectivity. This final SAR optimization led to the discovery of 1,3-dimethyl derivative 60, 8-(1-(3-(trifluoromethyl) benzyl)-1H-pyrazol-4-yl)-1,3-dimethyl xanthine, a high-affinity (K(i) = 1 nM) A(2B) AdoR antagonist with high selectivity (990-, 690-, and 1,000-) for the human A(1), A(2A,) and A(3) AdoRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759111     DOI: 10.1021/jm051268+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Exploring uncharted territories: predicting activity cliffs in structure-activity landscapes.

Authors:  Rajarshi Guha
Journal:  J Chem Inf Model       Date:  2012-08-16       Impact factor: 4.956

2.  New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile.

Authors:  Catia Lambertucci; Gloria Cristalli; Diego Dal Ben; Dhuldeo D Kachare; Chiara Bolcato; Karl-Norbert Klotz; Giampiero Spalluto; Rosaria Volpini
Journal:  Purinergic Signal       Date:  2007-09-19       Impact factor: 3.765

3.  The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.

Authors:  Stephanie Federico; Sara Redenti; Mattia Sturlese; Antonella Ciancetta; Sonja Kachler; Karl-Norbert Klotz; Barbara Cacciari; Stefano Moro; Giampiero Spalluto
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

4.  Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates.

Authors:  Rao V Kalla; Jeff Zablocki
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

5.  Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity.

Authors:  Marcel Lindemann; Sladjana Dukic-Stefanovic; Sonja Hinz; Winnie Deuther-Conrad; Rodrigo Teodoro; Cathleen Juhl; Jörg Steinbach; Peter Brust; Christa E Müller; Barbara Wenzel
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.